229 related articles for article (PubMed ID: 33145590)
1. Molecular Genetic Landscape of Sclerosing Pneumocytomas.
Boland JM; Lee HE; Barr Fritcher EG; Voss JS; Jessen E; Davila JI; Kipp BR; Graham RP; Maleszewski JJ; Yi ES
Am J Clin Pathol; 2021 Feb; 155(3):397-404. PubMed ID: 33145590
[TBL] [Abstract][Full Text] [Related]
2. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma.
Yeh YC; Ho HL; Wu YC; Pan CC; Wang YC; Chou TY
Mod Pathol; 2020 Mar; 33(3):391-403. PubMed ID: 31527710
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic and Transcriptomic Analysis of Sclerosing Pneumocytoma.
Yeh YC; Chu PY; Lin SY; Wang SY; Ho HL; Wang YC
Mod Pathol; 2024 Jan; 37(1):100354. PubMed ID: 37844870
[TBL] [Abstract][Full Text] [Related]
4. Identification of the BRAF V600E mutation in a patient with sclerosing pneumocytoma: A case report.
Jiang G; Zhang M; Tan Q; Lin S; Zeng Y; Liu C; Chen R; Zhou J
Lung Cancer; 2019 Nov; 137():52-55. PubMed ID: 31546071
[TBL] [Abstract][Full Text] [Related]
5. Genome profile in a extremely rare case of pulmonary sclerosing pneumocytoma presenting with diffusely-scattered nodules in the right lung.
Fan X; Lin L; Wang J; Wang Y; Feng A; Nie L; Wu H; Meng F; Xu H
Cancer Biol Ther; 2018 Jan; 19(1):13-19. PubMed ID: 29236566
[TBL] [Abstract][Full Text] [Related]
6. Unexpected diagnosis of multiple sclerosing pneumocytomas in a patient with chondrosarcoma of the hand.
Van Laer SL; Vandendriessche A; Somville J; Van Schil PE
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495182
[TBL] [Abstract][Full Text] [Related]
7. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung.
Amin RM; Hiroshima K; Miyagi Y; Kokubo T; Hoshi K; Fujisawa T; Nakatani Y
Pathol Int; 2008 Jan; 58(1):38-44. PubMed ID: 18067639
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Akt/mammalian target of rapamycin/4E-binding protein 1 pathway signal activation in round stromal and surface cells in patients with sclerosing pneumocytoma.
Hashisako M; Iwasaki T; Matsumoto T; Yamada Y; Miyamoto T; Taniguchi M; Oishi C; Oda Y
Pathol Res Pract; 2023 Apr; 244():154384. PubMed ID: 36878109
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
10. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
11. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
[TBL] [Abstract][Full Text] [Related]
12. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway.
Jahn SW; Kashofer K; Thüringer A; Abete L; Winter E; Eidenhammer S; Viertler C; Tavassoli F; Moinfar F
Am J Pathol; 2016 Jan; 186(1):15-23. PubMed ID: 26718977
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
14. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and gene mutation analysis of clear cell tumor of the lung.
Wu S; Pan D; Chen W; Ren F; Zheng D; Liu K
Indian J Pathol Microbiol; 2021; 64(2):362-368. PubMed ID: 33851636
[TBL] [Abstract][Full Text] [Related]
18. ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.
Vicentini C; Cantù C; Antonello D; Simbolo M; Mafficini A; Luchini C; Rusev B; Porcaro AB; Iacovelli R; Fassan M; Corbo V; Brunelli M; Artibani W; Scarpa A; Lawlor RT
Pathol Res Pract; 2018 Oct; 214(10):1675-1680. PubMed ID: 30190183
[TBL] [Abstract][Full Text] [Related]
19. Clustered pulmonary sclerosing pneumocytoma in a young man: a case report.
Shin SY; Kim MY; Lee HJ; Oh SY; Jang SJ
Clin Imaging; 2014; 38(4):532-535. PubMed ID: 24667045
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
